Navigation Links
Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
Date:11/21/2013

ATLANTA and CAMBRIDGE, Mass., Nov. 21, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc. announces the election of Anthony Zook, former head of Global Commercial Operations at AstraZeneca and past CEO of North America Operations for AstraZeneca and President of MedImmune, to its Board of Directors.

A 30-year veteran of the biopharmaceutical industry, Tony joined AstraZeneca (AZ) as Vice-President of Sales for the U.S. Business in 1999.  By 2001, Tony rose to Senior Vice President of AZ's US Commercial Operations and became Executive Vice President, CEO and President of AZ North America in 2006.  In 2008, Tony assumed responsibility for Global Marketing, and was also appointed President of AZ's biologic division, MedImmune.  In 2010, Tony transitioned to a global operations role when he was promoted to EVP of Global Commercial Operations for AZ, retiring from that position and the Company in 2013.  Under Tony's leadership, AZ commercialized 10 blockbuster brands and transformed AZ into a recognized commercial leader with an integrated, global customer approach. Following his 14-year career at AZ, Tony became CEO of Vivus to help revitalize the company but had to step down to address a health concern. He is currently a member of the Board of Directors of AltheRx Pharmaceuticals.

"I'm truly excited to join the Board of Directors of Inhibikase Therapeutics.  Inhibikase offers an exciting, and much needed new platform to treat patients with both bacterial and viral infections.  There is a significant need for new approaches to managing life threatening infectious diseases, and I believe Inhibikase will help revolutionize a new treatment approach in this area. "

Tony received his Associates Degree in Chemical Engineering from Penn State and his B.S. in Biology with a minor in Chemistry from Frostburg University.  Prior to joining AZ in 1999, Tony began his career in the pharmaceutical industry at Berlex Laboratories, Inc. as a pharmaceutical sales rep, culminating in his rise to Corporate Vice President and General Manager of Sales before his recruitment to AZ.

Tony joins Board members Dr. Steven Gilman, Executive Vice President and Chief Scientific Officer of Cubist Pharmaceuticals, Dr. Peter Mueller, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals, Ms. Lisa Evren, formerly of Merrimack Pharmaceuticals and Talisman Energy, Dr. Milton Werner, President & CEO of Inhibikase Therapeutics, Inc. and Strategic Advisor Mr. David Gryska, former CFO of Celgene to help lead Inhibikase through its next phase of growth.

"As Inhibikase continues to grow as an operational company with multiple programs at the clinical transition, Tony brings to the Company enormous experience that will be necessary to build an operational organization intending to commercialize its lead programs on its own," said Company President & CEO Dr. Milton Werner. "The Board will now be comprised of leaders in research, development, operations and finance whose insights will be of tremendous value as we embark on the further clinical evaluation of its lead programs in progressive multifocal leukoencephalopathy (PML) and polyomavirus-associated nephropathy (PVAN)."

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases.  Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action.  The Company's host-targeting strategy using clinically validated targets treat infectious disease with a low likelihood of stimulating resistance.  Founded in 2008 and headquartered in Atlanta, Georgia with offices in Cambridge, Massachusetts, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML), BK-virus associated nephropathy (PVAN), hard-to-treat hepatitis C, fungal and bacterial pneumonias as well as medical countermeasures for biodefense.

Contact:
Milton H. Werner, Ph.D.
President & CEO
Inhibikase Therapeutics, Inc.
(917) 494-0831


'/>"/>
SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
2. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
3. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
4. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
5. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
7. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
8. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
11. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):